Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. Co.'s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. We show 26 historical shares outstanding datapoints in our ALLK shares outstanding history coverage, used to compute ALLK market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALLK market cap history over the course of time is important for investors
interested in comparing ALLK's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALLK versus a peer is one thing; comparing
ALLK market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALLK can fluctuate over the course of history.
With this page we aim to empower investors researching ALLK by allowing them to research the ALLK market cap history. |
Free ALLK Email Alerts:
Video: The Importance of Market Cap
